



## Chembio Diagnostics to Report Second Quarter 2020 Financial Results on August 6, 2020

July 23, 2020

HAUPPAUGE, N.Y., July 23, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter 2020 after the close of trading on Thursday, August 6, 2020.

The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 844-369-8770 from the US or 862-298-0840 from outside the US or by accessing [www.chembio.com/investors/calendar-of-events/](http://www.chembio.com/investors/calendar-of-events/). A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US (using passcode 35830) or by accessing [www.chembio.com/investors/calendar-of-events/](http://www.chembio.com/investors/calendar-of-events/).

### About Chembio Diagnostics

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. The company's proprietary DPP technology platform, which uses a small drop of blood from the fingertip or alternative sample types, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at [www.chembio.com](http://www.chembio.com).

*DPP is Chembio's registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.*

### Investor contact:

Philip Taylor  
Gilmartin Group  
(415) 937-5406  
[investor@chembio.co](mailto:investor@chembio.co)



Source: Chembio Diagnostics, Inc.